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Advanced Glycation Endproducts and the Development of Accelerated 
Atherosclerosis in Diabetic Apolipoprotein E Deficient Mice 
Lisa Park, David Stern, and Ann Marie Schmidt. Department of Physiology, Columbia 
College of Physicians and Surgeons, New York, NY. (Sponsored by Joseph Madri, 
Department of Pathology, Yale University School of Medicine) 
Diabetes mellitus is associated with accelerated disease of both the micro- and 
macrovasculature, with the major morbidity and mortality in this population attributable to 
cardiovascular disease. Under hyperglycemic conditions, proteins and lipids are modified by 
non-enzymatic glycation, resulting in the formation and accumulation of advanced glycation 
endproducts, or AGEs. This heterogeneous class of compounds shares a number of 
characteristics including the ability to interact with specific cellular receptors, the best 
characterized of which is RAGE, the receptor for AGE. To investigate the possible contribution 
of AGEs to accelerated diabetic vascular disease, we studied apolipoprotein E deficient mice, 
which develop atherosclerosis on a normal chow diet. Diabetes was induced by multiple 
intraperitoneal injections of streptozotocin (55 mg/kg x 6 days). Sustained hyperglycemia was 
documented by elevated plasma glucose levels (>300 mg/dl) and a 1.8-fold increase in HbAic 
(p<0.05) in the streptozotocin-treated mice. Animals were sacrificed after 4, 6, 8, 10, and 24 
weeks of diabetes. Gross examination of the arterial tree at 8 and 24 weeks of diabetes revealed 
an increase in the size as well as the number of lesions in the diabetic mice when compared to 
their age-matched, non-diabetic controls. Quantitation of atherosclerotic lesions at the aortic root 
revealed a 3.7-fold increase in mean lesion area in diabetic mice (143,967 ± 12,319 pm2) 
compared with vehicle-treated controls (39,415 ± 9,875 pm") (p<0.0001). Total plasma 
cholesterol was 2.0-fold higher in diabetic mice (p<0.05), while total plasma triglycerides 
remained unchanged. Further analysis by density ultracentrifugation revealed a 1.4-fold increase 
in LDL cholesterol, and a 2.0-fold increase in the VLDL fraction, with relatively no change in 
HDL cholesterol. Increased AGE formation was confirmed by a 1.5-fold increase in AGE- 
reactive epitopes (p<0.05) as measured by ELISA using affinity-purified anti-AGE IgG in 
diabetic liver extracts. Immunohistochemistry of aortic lesions demonstrated markedly enhanced 
AGE-reactive epitopes in the vasculature of diabetic mice which co-localized with striking 
immunoreactivity for RAGE. Taken together, these data suggest an AGE-RAGE interaction in 
diabetic vessel wall may contribute to the pathogenesis of accelerated atherosclerosis in diabetes. 
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Introduction 
Heart disease was thought to be associated with diabetes as early as 1883, when 
Vergely recommended testing the urine of patients with angina for glucose [1 ]. Today we 
recognize cardiovascular disease to be the major cause of morbidity and mortality in 
people with diabetes mellitus. According to the 1987 National Hospital Discharge 
Survey, 77% of all hospitalizations for diabetic complications were for cardiovascular 
disease as compared to only 9% for renal disease, 6% for neurologic disease, 4% for eye 
disease, and 3% for other complications [2], In addition, for every diabetic patient older 
than 20 years of age who died of renal disease, nine died of coronary heart disease and 
two died of stroke [3]. Overall, in North America about 75% of patients with diabetes 
ultimately die of cardiovascular causes [4], 
Accelerated Atherosclerosis in Diabetes 
Although ischemic heart disease is a leading cause of morbidity and mortality in the 
general population, a number of epidemiological studies have shown that individuals with 
diabetes have an increased incidence of cardiovascular disease [5, 6]. The prevalence of 
coronary artery disease is as high as 55% in adults with diabetes, compared to a 2 to 4% 
prevalence in the general population [7]. Angina is more common in persons with 
diabetes; the incidence is 60% higher in diabetic men and 90% higher in diabetic women 
than their non-diabetic counterparts [8]. Mortality statistics also underscore the impact of 
atherosclerosis on the diabetic population. Data from the Framingham Heart Study 
demonstrate that mortality from cardiovascular disease in non-insulin dependent diabetes 

mellitus (NIDDM) is more than doubled in diabetic men and more than quadrupled in 
diabetic women when compared to their non-diabetic counterparts [9]. Additionally, 
results from the Joslin Study reveal that in patients with insulin dependent diabetes 
mellitus (IDDM), the mortality due to coronary artery disease is 35% by 55 years of age, 
far higher than the corresponding rate of 4-8% in persons without diabetes [9]. A 
particularly dramatic observation is the disproportionate impact of cardiovascular disease 
on pre-menopausal diabetic women compared with diabetic men, suggesting that this 
disease eliminates the well-known protection against ischemic heart disease normally 
experienced by women [10, 11]. 
Not only is atherosclerotic disease more prevalent in the diabetic population, but 
studies have shown that it is clearly accelerated and more extensive. In one large autopsy 
study, examination of coronary arteries from 23,000 individuals from 14 different 
countries demonstrated diabetes to be associated with an increase in the extent of 
atherosclerotic lesions regardless of the prevalence of coronary artery disease in the 
countries of origin [7], Numerous other autopsy studies have revealed that patients with 
diabetes tend to have more severe disease of the left anterior descending artery [12], a 
higher incidence of two- and three-vessel disease [13], and a greater diffuseness of 
distribution of the atherosclerotic lesions [141. Coronary angiographic studies in 
symptomatic patients have generally confirmed these findings [15]. 
Risk Factors for Atherosclerosis in Diabetes 
These data indicate that diabetic individuals develop premature and more severe 
atherosclerotic disease than their non-diabetic counterparts. What accounts for this 
increased risk? One explanation is that diabetes is associated with a number of 
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established risk factors for cardiovascular disease. Those of particular importance 
include dyslipidemia, hypertension, and obesity which may predispose patients with 
diabetes mellitus to atherosclerosis and its complications. 
Dyslipidemia 
The term dyslipidemia refers to alterations in plasma concentrations of lipids, as well 
as abnormalities in the composition and metabolism of lipoproteins. The Framingham 
Heart Study revealed that the dyslipidemia of diabetes includes hypertriglyceridemia, low 
levels of high-density lipoprotein (HDL) cholesterol, and alterations in low-density 
lipoprotein (LDL), with a predominance of triglyceride-rich, small, dense LDL particles 
[16]. These changes which occur in both IDDM and NIDDM are exaggerated by poor 
metabolic control and may be modified after good glycemic control with diet and 
appropriate insulin therapy [17]. 
Hypertriglyceridemia, reflecting increased plasma levels of very-low-density 
lipoproteins (VLDL), is very common in both IDDM and NIDDM. While the role of 
triglyceride as a cardiovascular risk factor in non-diabetic individuals is debatable, studies 
of diabetics consistently and strongly suggest hypertriglyceridemia to be a significant risk 
factor for cardiovascular disease in this population [18]. Recent studies have shown that 
the size distribution of VLDL particles in this setting is shifted towards smaller, denser 
particles in the VLDL density range. While the reason that hypertriglyceridemia 
predisposes the diabetic individual to atherosclerosis is unknown, it has been 
hypothesized that these small VLDL particles may play a role [19]. 
While LDL has long been considered the most atherogenic circulating lipoprotein in 
non-diabetic individuals, the role of LDL in diabetic atherogenesis is less clear. Most 
3 

studies show that LDL levels are nearly normal or only mildly elevated in both types of 
diabetes [20]. These studies have shown, however, that the composition of the LDL 
particles is altered [21], with a higher prevalence of small, dense LDL particles which may 
be more atherogenic than normal LDL [22]. 
The circulating level of HDL is widely recognized to be a favorable predictor of 
coronary artery disease, with levels inversely related to the risk of developing 
atherosclerosis in the non-diabetic population. In patients with IDDM and NIDDM, 
levels of HDL cholesterol are uniformly low, and most studies show an association 
between low levels of HDL-cholesterol and increased risk of cardiovascular disease in 
this patient population [23]. 
Hypertension and Obesity 
Hypertension is frequently associated with diabetes, with a prevalence twice as high 
in the diabetic population than in the non-diabetic population [24], Although hypertension 
may result from diabetic nephropathy, the frequency of hypertension appears to be higher 
in the diabetic population even in the absence of renal disease [25]. 
The importance of abdominal obesity, as a risk factor for cardiovascular disease has 
long been appreciated. In particular, visceral adiposity confers a greater risk than does 
subcutaneous adiposity, since the former is associated with insulin resistance and 
compensatory hyperinsulinemia. Although this factor may not appear to be simple to 
detect clinically, recent studies have shown that this risk can be semiquantified by the 
waist-hip ratio [26]. 
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Pathogenic Factors Unique to the Diabetic Population 
Although all of these known cardiac risk factors likely contribute to the 
development of atherosclerotic vascular disease in diabetes, multivariate analysis 
indicates that diabetic patients have an excess risk of cardiovascular disease relative to 
non-diabetic subjects even after adjustment for conventional risk factors [27]. In the 
Multiple Risk Factor Intervention Trial (MRFIT), 350,000 men (5,245 with diabetes) 
were followed prospectively for 6 years. Even after accounting for major risk factors 
(serum cholesterol, blood pressure, smoking) the diabetic men had a three- to six-fold 
increased risk for cardiovascular disease. The Nurses Health Study followed 1500 
diabetics among a total of 115,000 women, and found the incidence of cardiovascular 
disease to be five-fold higher in diabetics regardless of their cholesterol levels [28]. Thus, 
a large proportion of excess cardiovascular disease among diabetics cannot be explained 
by increases in known risk factors that affect the general population This observation 
suggests that there may be other atherogenic mechanisms which are unique to the diabetic 
population and play a critical role in the development of their disease. 
Hyperglycemia as a risk factor 
A number of epidemiological studies have strongly implicated hyperglycemia as an 
independent risk factor for cardiovascular disease in diabetes. The Tecumseh Study 
followed 921 men and 937 women over 40 years old who were without coronary artery 
disease upon entry into the study. After 12 years, diabetes was found to be a statistically 
significant independent risk factor for mortality due to coronary artery disease for both 
sexes. In addition, failure of a one-hour glucose challenge in patients not carrying the 
diagnosis of diabetes was also associated with excess mortality due to coronary artery 
5 

disease [29], Similar findings were noted in the Chicago Heart Association Detection 
Project which compiled data on 11,230 men and 8,030 women who were followed 
prospectively for 9 years. In this study, both diabetes and asymptomatic hyperglycemia 
were associated with increased mortality from coronary artery disease [30], 
One of the most compelling studies linking hyperglycemia with diabetic vascular 
complications is the Diabetes Control and Complications Trial (DCCT). The DCCT was 
a large, multicenter, controlled clinical trial designed to determine whether intensive 
treatment of hyperglycemia would affect the development and/or progression of 
complications in persons with IDDM. 1,441 patients were randomly assigned to 
conventional or intensive treatment with the goal of achieving glycemic levels as close to 
normal range as possible. Patients with hypertension, hypercholesterolemia, or obesity 
were excluded. The results showed that intensive therapy to decrease blood glucose 
concentrations to near normal levels effectively delayed the onset and slowed the 
progression of microvascular complications such as retinopathy, nephropathy, and 
neuropathy [31]. Additionally, the DCCT demonstrated that intensive treatment resulted 
in a significant reduction in cardiac risk factors such as mean total serum cholesterol, 
LDL cholesterol, and triglycerides. The number of combined major macrovascular 
events was almost twice as high in the conventionally treated group as in the intensive- 
treated group although the differences were not statistically significant [32]. 
Thus, the diabetic state in general and hyperglycemia in particular are associated with 
an increased risk for the development of cardiovascular disease. The mechanisms which 
may be involved in the pathogenesis of diabetic vascular disease will be discussed after a 
brief discussion of the basic mechanisms of atherosclerosis. 
6 

Mechanisms of Atherogenesis 
Much knowledge has accumulated over the last few years concerning the basic 
mechanisms of atherogenesis. The development of atherosclerotic lesions occurs over 
many years with the appearance of fatty streak lesions which progress to fibrous plaques. 
As these atheromata increase in size, progressive pathological events ensue including 
calcification, ulceration, thrombus formation, and aneurysmal dilation. Restriction of 
blood supply to vital organs results in angina, myocardial infarction, and stroke, all 
clinical events seen with increased frequency in diabetes. 
The earliest event that occurs during atherogenesis is the adhesion of monocytes to 
the endothelial lining of the vessel wall [33]. This interaction may be mediated by 
endothelial expression of mononuclear leukocyte adhesion molecule [34] or by integrins 
which are expressed on the surface of circulating leukocytes and bind to receptors on 
endothelial cells [35J. Therefore any factors that affect expression of adhesion molecules 
on either monocytes or endothelial cells may initiate fatty streak formation. 
Once these monocytes penetrate the endothelial cells, they enter the subendothelial 
space and mature into macrophages [36], Monocyte chemotactic protein-1 (MCP-1) is 
produced by macrophages and arterial smooth muscle cells and is believed to specifically 
attract monocytes to infiltrate the endothelial layer [37]. These monocytes are induced by 
various factors to differentiate into macrophages. While the identity of these agents is 
unknown, they are believed to be cytokines from T lymphocytes, which have been 
observed in close proximity to subendothelial macrophages [38]. Several cytokines have 
been implicated in the process of atherogenesis, including several interleukins, tumor 
necrosis factor, colony stimulating factor, fibroblast growth factor, vascular endothelial 
growth factor, platelet derived growth factor, and transforming growth factors a and (3 
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[38]. The regulation and mechanism of these factors is largely unknown, but it is likely 
that any effect on the expression and activity of these cytokines may influence the 
development of atherosclerotic disease. 
Once macrophages aggregate in the subendothelial space, they begin to accumulate 
lipids, predominantly cholesteryl esters, and develop into foam cells in the arterial wall. 
The lipids are derived from lipoproteins, leading to speculation on the mechanisms by 
which macrophages take up these lipoproteins. Much research has focused on the 
scavenger receptor on the surface of macrophages that bind oxidatively modified LDL 
[39, 40f Macrophages also take up large amounts of lipid by phagocytosis of lipoprotein- 
immune complexes. Lipoproteins that have been modified by either oxidation or 
glycation can stimulate antibody production which presumably leads to the formation of 
lipoprotein-immune complexes which can be taken up by macrophages in the arterial 
wall. Additionally, lipoproteins may aggregate in the artery wall by binding to 
extracellular matrix components. These lipoprotein-glycosaminoglycan complexes can 
also be taken up by macrophages, leading to foam cell formation [41). 
While not all fatty streak lesions are thought to progress to complicated 
atherosclerotic plaques, it is believed that all complicated lesions originate from fatty 
streaks. Lesions that progress to fibro-fatty plaques are characterized by smooth muscle 
cell migration from the media to the intima. These cells proliferate and synthesize 
connective tissue which is deposited in the vessel wall, leading to fibrous cap formation. 
The proliferation and activity of these smooth muscle cells is also likely under the 
influence of a number of growth factors, such as platelet derived growth factor [42], 
whose regulation may influence the development of this disease. 
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Atherogenesis in Diabetes 
The reason for the accelerated development of atherosclerosis in diabetes is not 
known. As discussed earlier, conventional risk factors are insufficient to explain the 
tremendous incidence of cardiovascular disease in diabetes, raising the likelihood that 
atherogenic mechanisms unique to the diabetic population must be involved. Under 
conditions of sustained hyperglycemia, proteins and lipids are modified by nonenzymatic 
glycation and oxidation, and we must consider the possibility that the products of these 
reactions may play a role in the development of diabetic vascular disease. 
Formation of Advanced Glycation Endproducts 
In diabetes, one of the central alterations in homeostasis is the nonenzymatic 
glycation of proteins and lipids leading initially to the formation of early reversible 
complexes and resulting ultimately in stable advanced glycation endproducts known as 
AGEs. [43, 44]. This process begins with the condensation of a sugar aldehyde or ketone 
with the reactive amino group of an amino acid residue (usually lysine) forming a Schiff 
base. Equilibrium is reached in a matter of hours at a steady-state level that is 
proportional to the glucose concentration. The Schiff base undergoes rearrangement over 
a period of days to weeks to form the more stable Amadori product, a 1-amino-1- 
deoxyketose compound. The Amadori product is then degraded into a variety of highly 
reactive carbonyl compounds such as 3-deoxyglucosone and sugar fragmentation 
products which react again with protein amino groups in a complex series of 
rearrangements to form a variety of intermediate and stable endproducts. These advanced 
glycation endproducts, or AGEs, undergo a rate of formation that is approximately 
second order with respect to the concentration of glycated amino groups, suggesting that 
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even modest elevations of glucose significantly increase AGE formation. In addition, 
because AGEs are the products of an irreversible reaction, the level of AGEs does not 
decline when hyperglycemia is corrected. Instead, these molecules continue to 
accumulate over the lifetime of the diabetic tissue component [45]. 
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AGEs arise from a complex series of dehydrations, rearrangements, and reactions that 
are poorly understood |46|. However, this heterogeneous class of compounds share a 
number of characteristics which include yellow-brown color, characteristic fluorescence, 
tendency to form cross-links, ability to generate reactive oxygen intermediates, and the 
ability to interact with specific cellular receptors. Thus far, only two AGE products have 
had their structures fully characterized. One is carboxymethyllysine [47], which is formed 
when oxygen free radicals cleave fructose-lysine residues. The other, pentosidine [48], 
forms when glucose moieties from two glycated amino acids (1 lysine, 1 arginine) link 
together. While it is unclear whether either of these two molecules have any clinical 
relevance, they may serve as markers for other products which may be directly involved 
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in the pathogenesis of disease states. In terms of how glycation products may play a role 
in atherogenesis in the setting of diabetes, much research has focused on AGE 
modification of two particular species: serum lipoproteins (primarily LDL) and structural 
proteins (primarily collagen). 
AGE modification of serum lipoproteins 
One known target of glycation is apolipoprotein B on the surface of LDL. Glycation 
of LDL under hyperglycemic conditions was first demonstrated more than 10 years ago 
by in vitro experiments which showed that the extent of LDL correlated with the duration 
of incubation and the concentration of glucose in the incubation mixture. In vivo 
glycation of apolipoprotein B was also found to be increased in diabetic patients, leading 
to the hypothesis that glycated LDL contributes to the accelerated atherosclerosis of 
diabetes [49]. 
A number of mechanisms involving glycated LDL have been investigated. Studies 
have shown that recognition of glycated LDL by the classic LDL receptor is impaired, 
increasing its half-life in plasma and its exposure to oxygen free radicals [50], The 
increased susceptibility of LDL to subsequent oxidative damage may enhance its uptake 
by subendothelial macrophages, stimulating foam cells formation [51]. Additionally, 
glycation of LDL may increase glucose-mediated covalent binding and sequestration 
within vessel walls, particularly if the matrix structural proteins have themselves been 
modified by glycation. LDL modification may also provoke an antibody response with 
the formation of potentially atherogenic LDL-immune complexes [52]. 
11 

AGE modification of extracellular matrix 
Because insoluble collagen is a long-lived protein existing in the matrix for years, it is 
a likely target for modification by glycation mechanisms. Studies have shown that in 
normal subjects, glycation of collagen in skin increases only slightly with age [47], 
Diabetic patients, however, exhibit a substantial increase in collagen glycation which 
correlates with levels of HbAlc, a marker of long-term glycemic control [53). 
The physical changes which occur upon glycation of collagen include the formation 
of covalent, heat-stable, intermolecular bonds [54]. The cross-links derived from AGE 
formation may be pertinent to atherogenesis for a number of reasons. The increased 
crosslinking of collagen may cause abnormal vascular rigidity and tone contributing to 
hypertension and as well as hyperpermeability and abnormal shear stresses involved in 
endothelial injury. Additionally, replication of vascular cells such as endothelial cells 
and smooth muscle cells, has been shown to be inhibited in the presence of glycated 
collagen matrix, thereby preventing repair processes that require the proliferation of these 
cells [55]. The glycation of collagen may also alter normal interactions of matrix ligands 
with plasma constituents. For example, it may cause plasma constituents such as 
lipoproteins and immune complexes to be more adherent to the vessel wall [56]. In 
addition, AGE modified matrix has been shown to be chemotactic to monocytes, 
facilitating their migration into the vessel wall, differentiation into macrophages, and 
formation of foam cells. This interaction, as well as a number of others, has been 
postulated to be mediated by specific cellular receptors that bind to a common structural 
element in AGEs. 
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Receptors for AGEs 
The first receptor for AGEs was identified on monocytes and macrophages |57). 
This discovery was of unique significance because it is the first receptor that recognizes a 
posttranslational protein modification known to occur extensively in vivo. Binding of 
AGEs to this receptor induces macrophage production of interleukin-1 and insulin-like 
growth factor 1, in addition to tumor necrosis factor a. These induced cytokines have 
been shown to activate proliferation of arterial smooth muscle cells as well as stimulate 
proliferation of glomerular mesangial cells and glomerular synthesis of collagen [58, 59]. 
AGE-specific receptors have also been found to be expressed on the surface of 
endothelial cells [60]. Initial studies showed that ligand binding to this receptor induces 
procoagulatory changes by increasing tissue factor activity and reducing thrombomodulin 
activity, resulting in vasoconstriction and focal thrombosis. This receptor, named RAGE 
(receptor for advanced glycosylation end products), was subsequently cloned and 
characterized [61], This molecule is a member of the immunoglobulin superfamily of cell 
surface molecules, whose extracellular region consists of one variable and two constant 
domains. Following this region is a single transmembrane-spanning region and short, 
highly charged cytosolic tail. Thus, RAGE is an integral membrane protein capable of 
serving as a cell-surface acceptor site for AGEs. 
In situ studies of endothelial RAGE using AGEs tagged with colloidal gold have 
demonstrated that after surface binding, AGEs are endocytosed and a portion of the 
ligand traverses the endothelial cell layer by transcytosis. Thus, RAGE provides a 
pathway for receptor-mediated uptake of ligands from the intravascular space with 
delivery to the subendothelium where AGEs may interact with extracellular matrix 
components [62]. This receptor is also expressed on the surface of mononuclear 
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phagocytes, and in vitro chemotaxis studies indicate that this receptor is able to mediate 
monocyte migration in response to AGEs [63]. This interaction may provide a 
mechanism for attracting and retaining macrophages at sites of AGE deposition in tissues 
and contribute to the development and progression of atheroclerotic lesions. 
Recent studies have also implicated the involvement of AGE-RAGE interaction in 
the endothelial expression of VCAM-I, which has been associated with early phases of 
atherosclerosis [64, 65], In vitro studies of human endothelial cells exposed to AGEs 
showed increased expression of VCAM-I as measured by ELISA and mRNA studies, and 
this effect was blocked by antibodies to RAGE. In vivo studies in which AGE-albumin 
was infused into normal mice also showed enhanced expression of VCAM-I in the 
vasculature by immunohistochemical analysis [66], These data suggest a unique pathway 
by which AGEs may contribute to the pathogenesis of diabetic vascular disease. 
Animal Models of Diabetes 
Our understanding of diabetes mellitus has benefited greatly by the use of animal 
models of disease. The use of animals, rather than humans, in diabetes research has 
multiple advantages. In studying the pathogenesis of this disease, animal models permit 
more complete analysis of anatomical and biochemical changes in organs which are 
generally inaccessible in humans. Use of a homogeneous population maintained under 
well-controlled conditions also allows for the isolation of one of many different factors 
which may influence the development of disease in humans. Additionally, animal 
models provide us with the opportunity to investigate the toxicity and efficacy of 
therapeutic measures to prevent the development or progression of the disease and its 
complications. 
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A number of animals have been used to study diabetes. These include non-human 
primates, dogs, swine, and other large animals in which diabetes can be induced using 
viruses, chemical agents, or by partial pancreatectomy. However, these animal models 
pose many technical difficulties and high maintenance costs in cultivating large colonies 
necessary for statistically significant sample sizes. These animals also do not allow for 
genetic manipulation in order to dissect out the underlying biochemical and molecular 
causes for this disease. For this reason, the rodent has been an often used model which 
has been well-characterized. Some of the more commonly used genetic mouse models of 
diabetes include the autosomal recessive db/db mouse and the NOD (non-obese diabetic) 
mouse. Their use in the specific study of diabetic vascular disease has been limited, 
however, by the inherent resistance of mice to the development of atherosclerotic disease 
[67], 
Recently, a transgenic mouse has been developed, the apo'ipoprotein E deficient 
mouse, which develops advanced atherosclerosis on a normal chow diet [68, 69]. This 
animal develops hypercholesterolemia primarily due to elevated levels of very low and 
intermediate density lipoproteins, and demonstrates a full range of atherosclerotic lesions 
from fatty streaks to fibrous plaques. These lesions are consistently distributed 
throughout the arterial tree in sites of known predilection. Thus, by using chemical 
agents to induce diabetes, this mouse may provide us with a useful animal model to study 
mechanisms of accelerated atherosclerosis in diabetes. 
15 

Statement of Purpose 
My objective is to develop and describe an animal model of accelerated 
atherosclerosis by inducing diabetes in apolipoprotein E deficient mice. We believe this 
model will provide an important means to study the lipid-dependent and lipid- 
independent mechanisms which underlie accelerated atherosclerosis in diabetes. We also 
hope to use this model to test our hypothesis that the formation and accumulation of 
AGEs under sustained hyperglycemia, and their interaction with the cellular receptor, 
RAGE, contribute to the pathogenesis of this disease. 
16 

Materials and Methods 
Preparation and staining of aortic tissue sections were performed with the technical 
assistance of Yan Lit and Yu Shan Zou. All other methods described below were 
performed by Lisa Park. 
Animals 
Apolipoprotein E deficient mice on a C57B1/6J background (N10 generation, 99% 
homology) were obtained from The Jackson Laboratory (Bar Harbor, ME) and bred in a 
barrier facility with controlled temperature (65-75° F) and humidity (40-60%). The mice 
were maintained on a 12 hr light/dark cycle and given free access to food and water. The 
animals were maintained on a normal rodent chow diet (Purina 5001) for the duration of 
the experiments. Diabetes was induced in male apolipoprotein E deficient mice at 7 
weeks of age, using multiple intraperitoneal injections of streptozotocin (STZ, Sigma) 
dissolved in a sterile citrate buffer (pH 4.5). STZ (55 mg/kg) or vehicle alone was 
administered for 6 days. Plasma glucose concentration was determined by colorimetric 
assay (Sigma) using blood obtained from the tail vein. Mice were considered diabetic if 
glucose levels were greater than 300 mg/dl on two separate occasions. Glycosylated 
hemoglobin was measured from packed red cells by affinity chromatography (Pierce). 
Mice were euthanized after 4, 6, 8, 10, and 24 weeks of diabetes using an intraperitoneal 
injection of ketamine and xylazine. Blood was drawn through a 30 gauge needle via the 
inferior vena cava. The liver and kidneys were resected and frozen immediately at -80°C. 
A thoracotomy was performed and the beating heart and arterial tree were perfused with 
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phosphate-buffered saline (PBS, GIBCO) via the inferior vena cava. The heart and aorta 
were dissected away from the thorax and stored immediately in formalin or frozen at 
-80°C until processed for further analysis. 
Quantitation of atherosclerotic lesions 
Quantitative analysis of atherosclerotic lesions was performed on sections from the aortic 
sinus. The hearts were fixed in 10% formalin, embedded in 25% gelatin and frozen. 
Cryostat sections were cut 10 microns thick throughout the aortic sinus, stained with oil 
red O and counterstained with hematoxylin and light green. For each animal, fatty lesion 
areas were measured by computer assisted image analysis (Zeiss Image, Media 
Cybernetics) in five consecutive sections each separated by 80 microns. The mean lesion 
area per section per animal was calculated for each group of mice. 
Lipoprotein analysis 
Mice were fasted for four hours prior to obtaining plasma for lipoprotein analysis. Blood 
was collected by retro-orbital puncture in 0.005M EDTA, and plasma concentrations of 
cholesterol and triglyceride were measured using commercial kits (Boehinger 
Mannheim). VLDL (d < 1.006 g/ml), IDL/LDL (d = 1.006-1.063 g/ml), and HDL 
(d= 1.063-1.21 g/ml) were separated by sequential density ultracentrifugation of pooled 
plasma. Subfractionation of the VLDL fraction was performed by overlaying with 
nonlinear salt gradients and removing the top layer after three successive centrifugations. 
Levels of cholesterol and triglyceride were measured in each of these fractions. 
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AGE ELISA 
Frozen mouse livers were homogenized and incubated in a non-ionic detergent, 1% n- 
octylglucoside (Boehinger Mannheim), at 4°C overnight. After ultracentrifugation, the 
supernatant was collected and protein concentration determined by the Bradford assay 
(Biorad). ELISA was performed on these samples using chicken anti-AGE IgG primary 
antibody. The secondary antibody was a peroxidase-conjugated rabbit anti-chicken IgG 
(Sigma). Spectrophotometric readings were taken using o-phenlenediamene 
dihydrochloride (OPD, Sigma) as the chromagen. 
Immunohistochemistry for AGE and RAGE 
Aortic tissue was fixed in 10% formalin; cross-sectional and longitudinal sections were 
prepared. Immunohistochemistry for AGE was performed using chicken anti-AGE IgG 
and immunohistochemistry for RAGE was performed using rabbit anti-RAGE IgG. 
Peroxidase-conjugated rabbit anti-chicken IgG and goat anti-rabbit IgG (Sigma) were 
used as secondary antibodies. Non-immune rabbit and goat serum were used as negative 
controls. 
19 

Results 
1. Hyperglycemia is induced in apolipoprotein E deficient mice treated with 
streptozotocin. 
Our goal was to investigate the role of hyperglycemia on the development of 
atherosclerotic disease without the confounding factor of concurrent insulin 
administration to maintain animal viability. Therefore, we used a multiple low-dose 
injection regimen of streptozotocin and documented hyperglycemia on day 10 following 
the start of treatment. These streptozotocin-treated mice were relatively healthy as 
evidenced by adequate coat color, activity, weight gain, and absence of ketonuria. Plasma 
glucose levels measured during the course of the experiments ranged from -350-500 
mg/dl for the STZ-treated mice as compared with -130-160 mg/dl for the citrate-injected 
controls (see Figure 1). Overall, these levels were nearly tripled for the mice injected 
with streptozotocin as compared with their citrate-treated controls. 
Glycosylated hemoglobin, or HbAic, is an early glycation product which reflects 
average blood glucose levels over a two to three month period. Measurements were 
performed by affinity chromatography on packed red blood cells. Mean levels of HbAic 
were 7.18 ± 1.7% in the diabetic mice compared to 4.03 ± 1.2% for their age-matched 
controls (see Figure 2). Thus, diabetic mice demonstrated a 1.8-fold higher (p<0.05) 
glycosylated hemoglobin over their controls, confirming a state of sustained 
hyperglycemia. 
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Figure 1 Plasma glucose concentrations of apolipoprotein E deficient mice after treatment with 
streptozotocin or citrate. Animals were treated with intraperitoneal injections of STZ (55 mg/kg) or 
citrate buffer for 6 days. Plasma glucose concentration was determined by colorimetric assay on blood 
obtained from the tail vein. Glucose levels were nearly tripled for the streptozotocin-treated mice compared 
to the citrate-treated controls. 
I 
HbA1c 
Figure 2 Glycosylated hemoglobin levels after treatment with streptozotocin or citrate. Levels of 
HbAlc were determined by affinity chromatography on packed red blood cells obtained 8 weeks after 
treatment with STZ or citrate. Mean levels were 1.8-fold higher in the diabetic animals compared to the 
non-diabetic controls (p<0.05). 
21 

2. Diabetic mice demonstrate accelerated atherosclerosis. 
It has been previously described that the apolipoprotein E deficient mouse develops 
atherosclerotic lesions on a normal rodent chow diet. These lesions develop throughout 
the aorta and its principal branches at known sites of predilection (see Figure 3). Gross 
lesions first appear as small yellowish-white nodules detectable at 10 weeks of age which 
increase in size and progress in appearance to typical fibrous plaques at approximately 20 
weeks of age. 
Figure 3 Sites of predilection for lesion development in the apolipoprotein E deficient 
mouse (reprinted with modification from Nakashima, 1994). These include the aortic root, lesser 
curvature of the aortic arch, principal branches of the thoracic aorta, carotid artery, principal 
branches of the abdominal aorta, aortic bifurcation and iliac artery. 
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By inducing diabetes in these mice, we investigated whether the development of 
atherosclerosis would be accelerated in this animal model. Mice were dissected at 4, 6, 8, 
10, and 24 weeks of diabetes. Fatty streak lesions were observed in both diabetic and 
control mice, as expected. These generally appeared first at the aortic root and at the 
lesser curvature of the arch, with progression to each of the principal branches of the 
thoracic aorta, beginning proximally. At each timepoint examined, the lesions were 
consistently larger in size and more extensive in the diabetic animals when compared to 
their age-matched controls. For example, after 10 weeks of hyperglycemia, the diabetic 
mouse had discrete lesions at each of the thoracic branchpoints with nearly complete 
occlusion of the vessels (see Figure 4). This is in marked contrast to an age-matched 
control mouse which had some mild fatty streaks, mainly at the aortic root, which were 
difficult to appreciate grossly. 
With increasing age, atherosclerotic lesions progressed throughout the aorta and its 
principal branches. After 24 weeks of diabetes, the STZ-treated mice demonstrated a 
marked increase in the size as well as the number of lesions over their age-matched 
controls throughout the arterial tree, particularly in the descending thoracic aorta, the 
renal artery branches, and at the iliac bifurcation (see Figure 5). The appearance of these 
lesions was typical of fibrous plaques with substantial narrowing of the arterial lumen, in 
some cases to the point of -95% occlusion. 
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Figure 4 Gross examination of the proximal aorta under dissection microscopy. (4x 
magnification) Aortic specimens were treated with a retrograde injection of methylene blue to 
highlight the white atherosclerotic lesions developing within the aortic lumen. Diabetic (top) and 
control (bottom) mice were 16 weeks of age (10 weeks of diabetes). 
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Figure 5 Gross examination of 
thoracic and abdominal aorta 
under dissection microscopy after 
24 weeks of diabetes. (2x 
magnification) These specimens 
from diabetic (top, each panel) and 
control (bottom, each panel) mice 
demonstrate accelerated 
atherosclerotic disease in diabetes at 
multiple levels of the arterial tree: A) 
descending thoracic aorta B) renal 
arteries C) iliac bifurcation 
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In order to quantitate the degree of atherosclerosis for comparison between the 
diabetic and control groups, histological specimens from the aortic root were obtained 
from the mice in a standardized manner. Cryostat sections were cut specifically at the 
aortic sinus beginning at the point of vessel rounding once the three valves were 
visualized. These were stained using oil-red-O, a lipid-specific stain, and counterstained 
with hematoxylin and light green. 
Light microscopic examination of aortic tissue sections from all of the mice 
demonstrated fatty lesions. In the non-diabetic mice, the vascular lesions were 
characterized generally by small groups of lipid-filled cells found primarily adjacent to 
valve attachment sites. In contrast, specimens taken from diabetic mice after only 6 
weeks of hyperglycemia demonstrated more advanced atherosclerotic lesion formation. 
These consisted of foam cells intermixed with spindle shaped smooth muscle cells 
tending to form a fibrous cap on top of the lesion, (see Figure 6) 
Quantitation of the fatty streak lesion areas was performed in 5 consecutive sections 
each separated by 80 microns, and the mean lesion area per section was calculated using 
computer-assisted image analysis (see Figure 7). The mean lesion area in the control 
group of 16 week old apolipoprotein E deficient mice was 39,415 ± 9875 pm2. In 
comparison, at the same age, but after 8 weeks of sustained hyperglycemia, the mean 
lesion area was 143,967 ± 12,319 pm2; a statistically-significant 3.7-fold increase over 
the non-diabetic controls (p<0.0001). A similar experiment after 6 weeks of diabetes 
revealed a 3-fold increase (p<0.05) in the size of diabetic atherosclerotic lesions. 
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Figure 6 Oil red O-stained aortic sections from diabetic and control apolipoprotein E 
deficient mice fed a normal chow diet. (40x magnification) Aortic sections were stained with 
oil red O and counterstained with hematoxylin and light green. Diabetic mice (B,D,F) 
demonstrated marked accelerated atherosclerotic lesion development after 8 weeks compared to 
the non-diabetic age-matched controls (A,C,E). 
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Quantitation of atherosclerotic lesions 
Figure 7 Aortic sinus lesion areas for diabetic and control apolipoprotein E deficient mice. 
Quantitation of atherosclerotic lesions was performed using computer-assisted image analysis 
(ImagePro, Media Cybernetics). Mean lesion area for diabetic mice (143,967 ± 12,319 jinr) was 
3.7-fold higher compared to age-matched controls (39,415 ± 9875 gm2) after 8 weeks of diabetes 
(p<0.0001) 
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3. Lipid analysis 
To document the level of plasma lipids over time, mice were fasted for four hours 
prior to sacrifice at various timepoints. Blood was obtained via the inferior vena cava, 
and total plasma cholesterol and triglyceride levels were determined by colorimetric 
assay. Plasma cholesterol levels of the diabetic mice were approximately double that of 
the control mice after 4 weeks of diabetes, while the triglyceride levels remained 
unchanged. The cholesterol levels of the diabetic mice after 8 weeks of diabetes ranged 
from -650-1800 mg/dl with a mean of 1244 mg/dl whereas those of the age-matched 
controls ranged from -450-630 mg/dl with a mean of 543 mg/dl. There was greater 
variability in the cholesterol levels of the diabetic animals, with levels that were 
consistently higher than those of the non-diabetic controls (see Figure 8). 
In order to determine the distribution of cholesterol among the different lipoprotein 
fractions, density ultracentrifugation was performed on pooled plasma (see Figure 9). 
This analysis revealed that the greatest cholesterol increase occurred in the VLDL 
fraction, which showed a 2.0-fold increase in the diabetic mice over their age-matched 
non-diabetic controls. There was also a 1.4-fold increase in the LDL cholesterol level. 
HDL cholesterol remained relatively unchanged between the two groups. 
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Figure 8 Plasma cholesterol levels of diabetic and control mice. Plasma cholesterol concentrations 
after a 4 hour fast were determined by colorimetric assay. At 4, 6, and 8 weeks of diabetes, the cholesterol 
levels of the diabetic mice were two-fold higher than the age-matched controls. 
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Figure 9 Cholesterol concentrations of lipoprotein fractions. Lipoprotein fractions were separated by 
density ultracentrifugation of pooled plasma. The greatest increase was in the VLDL fraction, which was 
2.0-fold higher in the diabetic mice over the non-diabetic controls. LDL cholesterol increased 1.4-fold, 
while HDL cholesterol was relatively unchanged. 
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4. AGE formation is enhanced in these diabetic animals. 
AGEs were measured directly in protein extracts from mouse liver by ELISA, using 
affinity-purified anti-AGE IgG antibody developed in our laboratory. Mean AGE levels 
in the diabetic mice were 144 ± 26 pg/dl as compared with 98 ± 17 |ig/dl in the age- 
matched controls. Thus, diabetic mice demonstrated a 1.5-fold (p<0.05) increase in 
AGEs over their age-matched, non-diabetic controls as measured in this highly 
vascularized organ (see Figure 10). 
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Figure 10 Evidence of elevated AGEs in diabetic mice compared with non-diabetic controls. Levels 
of AGEs were measured directly by ELISA using affinity-purified anti-AGE IgG in mouse liver extracts. 
Diabetic mice showed a 1.5-fold increase (p<0.05) in AGEs compared to non-diabetic animals. 
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5. AGEs accumulate in the vasculature of diabetic mice. 
In order to investigate the possible role of AGEs in the development of accelerated 
atherosclerosis, we sought to identify AGEs within the vasculature. We performed 
immunohistochemical analysis of aortic tissue sections after 6 weeks of hyperglycemia. 
The diabetic mouse shows increased staining for AGE reactive epitopes in the vessel 
wall, with the highest levels deposited in the endothelium of the tunica intima as well as 
in the collagenous fibers of the tunica adventitia (see Figure 11). 
6. RAGE expression is enhanced in the diabetic vessel wall. 
Previous studies have shown that the receptor for AGEs, RAGE, is expressed by 
endothelial cells as well as smooth muscle cells in the vasculature. We investigated the 
expression of RAGE in our mouse model by immunohistochemical analysis of aortic 
sections using polyclonal monospecific anti-RAGE IgG. There is enhanced expression of 
RAGE in the vessel wall of the diabetic mouse as compared to its non-diabetic control. 
This staining is prominent throughout the endothelium and the smooth muscle cells of the 
tunica media after only 6 weeks of diabetes (see Figure 12). 
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Figure 11 Immunohistochemical 
staining for AGE in diabetic (top) and 
control (bottom) mouse aorta. (40x 
magnification) Tissue sections were 
stained with polyclonal anti-AGE IgG. 
Aortic sections from diabetic mice 
demonstrate a marked increase in AGE- 
reactive epitopes in the tunica intima and 
tunica adventitia when compared to non¬ 
diabetic control mice. 
Figure 12 Immunohistochemical 
staining for RAGE in diabetic (top) 
and control (bottom) mouse aorta. 
(lOOx magnification) Tissue sections 
were stained with polyclonal anti-RAGE 
IgG. Diabetic mice demonstrated marked 
RAGE expression in the endothelial and 
smooth muscle cells of the vasculature 
compared to the non-diabetic controls. 

Discussion 
Development of an animal model of accelerated atherosclerosis 
One of the primary objectives of this study was to develop a mouse model of 
accelerated atherosclerosis in diabetes. By using a multiple low-dose injection regimen 
of streptozotocin, we were able to achieve sustained hyperglycemia and animal viability 
in the apolipoprotein E deficient mouse. Because these animals were maintained without 
concurrent insulin administration, we were also able to avoid the introduction of 
hyperinsulinemia as an independent risk factor for cardiovascular disease. 
The diabetic mice exhibited significantly accelerated atherosclerosis when 
compared to their age-matched, non-diabetic counterparts at multiple timepoints. The 
initial lesions appeared earlier in the diabetic animals with a significant increase in size 
observed upon gross examination of the aorta after only 6 weeks of diabetes. 
Quantitation of fatty streaks at the aortic root demonstrated a nearly four-fold increase in 
the size of the lesions by 8 weeks of diabetes, and by 24 weeks there was extensive 
atherosclerotic disease throughout the arterial tree with nearly 100% occlusion of major 
branches. 
Not only were the atherosclerotic lesions larger in size, but the disease was also 
more extensive and advanced in the diabetic animals. Histologic examination revealed 
foam cell and fibrous cap formation in aortic sections after 8 weeks of diabetes, while the 
non-diabetic animals demonstrated early fatty streak lesions at the same age. Thus, by 
chemically inducing diabetes in this mouse, we have created an experimental model of 
accelerated atherosclerosis. 
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By using the apoiiprotein E deficient mouse which has a natural propensity to 
develop atherosclerosis, we eliminated the need to administer an atherogenic diet. 
Previous studies have attempted to overcome the inherent atherosclerosis resistance of 
mice by feeding a diet consisting of 1.25% cholesterol, 15% saturated fat, and 0.5% 
cholic acid [70], This diet contains 10-20 times the amount of cholesterol found in a 
typical human diet and contains an unnatural dietary substance, cholic acid. When fed 
this cholesterol-rich food, certain inbred mouse strains, such as C57BL/6J, will show 
atherosclerotic changes [71]. However, the lesions that do eventually develop are 
relatively immature in quality and restricted in distribution to the aortic arch. Another 
mouse strain, BALB/c, has also been shown to develop atherosclerosis while fed an 
atherogenic diet [72], When this strain is treated with STZ, accelerated atherosclerosis 
does result. However, the diabetic mice on normal chow develop no vascular disease, 
suggesting that both dietary as well as diabetic factors act in combination in this model. 
By eliminating the need for an atherogenic diet, the apolipoprotein E deficient mouse 
allows us to isolate the effects of hyperglycemia alone. 
Lipid analysis of the diabetic apolipoprotein E deficient mouse revealed an 
increase in total plasma cholesterol. Further investigation demonstrated, however, that 
the greatest increase did not occur in LDL cholesterol, but in the VLDL fraction. The 
atherogenic properties of these particles is largely unknown and currently the subject of 
much debate and research. We therefore believe that the hypercholesterolemia in this 
mouse model does not preclude the presence of lipid-independent mechanisms which 
likely contribute to the development of atherosclerotic disease. 
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There are a number of other transgenic mice which have been recently developed 
and show promise in the study of atherosclerosis. These include the apolipoprotein B 
transgenic mouse [73, 741 as well as the LDL receptor deficient mouse [75], Both of these 
animals develop high plasma levels of LDL cholesterol and severe atherosclerotic lesions 
in response to a high-fat diet. This “human-like” lipid profile makes these mice 
potentially interesting models for the study of diabetic vascular disease. 
AGE-RAGE in cardiovascular disease 
Another objective of this study was to investigate the possible role of AGE 
formation and accumulation in the development of diabetic cardiovascular disease. This 
animal model of accelerated atherosclerosis in diabetes provides us with a unique tool to 
investigate the contribution of AGEs in vivo. Under conditions of sustained 
hyperglycemia, AGE formation was increased, as measured in liver extracts from diabetic 
mice. We also observed accumulation of AGEs in the diabetic vessel wall by 
immunohistochemical analysis of aortic tissue sections. At the same time we also 
observed enhanced expression of the receptor, RAGE, in the endothelium and smooth 
muscle cells of the aorta after only 6 weeks of diabetes, a timepoint characterized by the 
presence of accelerated atherosclerotic lesions. These data taken together are consistent 
with the hypothesis that AGE formation and accumulation in sustained hyperglycemia 
may contribute to the pathogenesis of accelerated atherosclerosis via RAGE-mediated 
mechanisms. 
These observations and this experimental system lead to many possible avenues of 
inquiry. What is the identity of the AGE-modified proteins? What are the pathways that 
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are activated by the binding of AGE to RAGE? And more importantly, is this AGE- 
RAGE interaction critical to the development of diabetic vascular disease? And can we 
prevent diabetic complications with therapeutic agents which inhibit this interaction? 
Further studies to investigate these possibilities are currently underway. One experiment 
involves administering aminoguanidine, a chemical which prevents the formation of 
AGEs. As a potential therapeutic agent, however, this compound has limited use 
clinically. By the time many individuals are diagnosed with diabetes, particularly 
NIDDM, they have been hyperglycemic for a long period of time and have already 
accumulated AGEs. Aminoguanidine may prevent further AGE formation, but will have 
no effect on the activity of the long-lived proteins which have already been modified. 
Thus, another strategy involves inhibiting the binding of AGEs to their receptor. This 
may be accomplished using soluble RAGE (sRAGE), which consists of the extracellular 
portion of the AGE receptor. By administering sRAGE, we may competitively inhibit 
binding of AGEs to their cellular receptor and prevent activation of potentially pathogenic 
mechanisms. Studies injecting diabetic apolipoprotein E deficient mice with sRAGE are 
currently being conducted in hopes of preventing or delaying the development and 
progression of diabetic vascular complications. 
Other experiments include creating transgenic mice with a deletion or cell-specific 
overexpression of RAGE. These mice may then be crossed with atherosclerosis-prone 
mice, to observe the effects on the development of disease. Such studies are currently 
underway in our laboratory. 
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AGE-RAGE in other diabetic vascular complications 
In addition to its role in cardiovascular disease, AGEs have been implicated in a 
variety of diabetic complications throughout the microvasculature as well. Data from the 
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) [76] demonstrate a 
strong correlation between hyperglycemia and the incidence and progression of 
microvascular disease such as diabetic retinopathy and nephropathy. Immunostaining of 
renal tissue in patients with diffuse diabetic glomerulosclerosis reveals extensive 
deposition of AGEs in the vessel wall and Bowman’s capsule [77], Additionally, 
aminoguanidine has been shown in diabetic rats to prevent the thickening of glomerular 
basement membrane and trapping of IgG molecules seen in diabetic renal disease [78], 
Another important diabetic complication in which AGEs are likely to play a role 
is in the development of proliferative diabetic retinopathy (PDR), the leading cause of 
blindness over the age of 65. AGEs have been detected in the vitreous of human diabetic 
subjects with PDR [Park, L unpublished observations]. They have also been identified the 
streptozotocin-treated diabetic rat [79]. This research has shown that retinal vessels in 
these animals demonstrate the characteristic fluorescence of AGEs which correlate with 
the degree of background retinopathy. Interestingly, treatment with aminoguanidine 
decreases the level of detectable AGEs and inhibits progression of this disease. 
These data indicate that AGEs likely play a critical role in the development of 
accelerated disease throughout the micro- and macrovasculature of diabetic patients. By 
investigating their interaction with the cellular receptor, RAGE, and the subsequent 
pathogenic pathways, we may identify new strategies for possible therapeutic intervention 
in preventing the complications of diabetic disease. 
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